Lilly’s Foundayo is reportedly off to a strong start. The company’s obesity only recently hit the market, and a report from ...
Depth-of-response measures, including MRD and symptom endpoints, reinforced broad clinical benefit beyond PFS, supporting consideration as a new second-line standard for eligible patients. Infection ...
However, President Trump posted on his Truth Social account this morning that he is “pleased to announce the new leadership ...
Model N’s Michael Grosberg breaks down the accelerated complexity, policy disruption, and data gaps testing manufacturer market access and revenue management strategies. In the debut episode ...
In a conversation with Pharmaceutical Executive, Morten Graugaard, CEO, Orbis Medicines, discussed FDA’s approval of Icotyde ...
Behavioral data indicate substantial underuse: ~40% delay epinephrine and 56% of caregivers fear needle-based auto-injectors, ...
FDA required additional post-approval evaluation of myocardial infarction, stroke, and other cardiovascular events because ...
In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in ...
Formal triggers to reassess, restrict, or withdraw accelerated approvals are urged when postmarketing confirmatory trials lag ...
In an interview with Pharmaceutical Executive, Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, ...
With the patent cliff looming, biosimilars can play an important role in the coming years. According to Newcomer, there are ...
Marking a fundamental shift in how we define acceptable clinical proof, it has indicated that one well-controlled trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results